Hong-Rui Liu obtained the Bachelor's degree in clinical medicine from the Second Mmilitary Medical University in 1991, and obtained the Ph.D. of pharmacology from the China Medical University in 2005. Dr. Liu joined the School of Pharmacy, Fudan Unversity in 2007, and worked as a lecturer to an associate professor. Her research interests include screening of antitumor drugs, respiratory pharmacology and cardiovascular pharmacology. She presided over or participated in a number of research programs including National Science Foundation, the provincial project and the horizontal joint research of new drug development. She has published more than 20 research articles and obtained 3 patents for invention.
Screening of antitumor drugs; Protection of cardiovascular drugs; Liver protection drugs; Gastrointestinal protection of drugs
Education
1999/09-2005/07, Basic medical School, Chinese Medical University, Master & Ph. D.
1985/08-1991/07, Second Military Medical University, Undergraduate
Professional Experiences
2007/01-present Fudan University, College of Pharmacy, Lecturer & Associate professor
2005/10-2007/01, Institute of Cell and Biochemistry, Shanghai Academy of Life Sciences，Chinese Academy of Sciences, Research Assistant
1997/09-2005/09, Basic medical School, China Medical University, lecturer
Teaching activities
The courses I attended include “Pharmacology”, “Molecular Pharmacology”, "Introduction to Clinical Medicine", "Medical treatment of common diseases", "Comprehensive knowledge and skills of pharmacy", "Clinical medicine basis for pharmaceutical research" and "Common medical test indexes and their clinical significance", "Common toxic diseases and rescue" and “XY and Medicine ” et al.
I had completed the teaching reform projects of undergraduate and postgraduate teaching, and won the Gold Teacher title from the first licensed pharmacist continuing education of Shanghai Municipal Bureau of Pharmacy and Drug Administration at 2010. I am now the Associate editor of "Introduction to clinical medicine", which is the "Thirteen-Five" Planning Textbook of the National General Medical College.
Grants & Projects
1. A project of Major new drug creation in science and technology department (2018ZX09301044-006), “A preclinical study of new type of IDO inhibitor KYQ-2013 as a new drug for tumor immunotherapy”, 2018/01-2020/12, Executing, Project leader
2. Traditional Chinese Medicine modernization of Shanghai Science and Technology Commission(10dz1972100), “a kind of new candidate for the protection of myocardial ischemia clinical study of SPRC”, 2010/07-2013/06, Completed, Project leader
3. The 14th subprojects of Major new drug creation in science and technology department "Comprehensive new drug research and development technology platform"(2009ZX09301-011), “The research and development of SPRC as a new type of drug candidates for protection of myocardial ischemia, 2008/01-2011/06, Completed, Project leader
4. National Natural Science Foundation Project (81272391), The role of acetylation heat shock protein HSP90 in tumor metastasis, 2013/01-2016/12, Completed, Participant
5. National Natural Science Foundation Project (81273584), The establishment of a new type of external BIO-PK/PD model system and the mechanism of SPRC metabolism toxicity, 2013/01-2016/12, Completed, Participant
6. National Natural Science Foundation project (81173054), The role of cardiac protection of hydrogen sulfide in heart failure and the molecular mechanisms related STAT3 pathway, 2012/01-2015/12, Completed, Participant
7. National Natural Science Foundation project (30772565), The molecular mechanism of hydrogen sulfide (H2S) and glutathione-?-lysis enzymein in myocardial ischemia, 2008/01–2010/12, Completed, Participant
Selected Publications（latest 5 yrs，<20 papers）
1. Wenjing Zai, Wei Chen, Jingyun Luan, Jiajun Fan, Xuyao Zhang, Zimei Wu, Tao Ding, Dianwen Ju, Hongrui Liu*. Dihydroquercetin (DHQ) Ameliorated Acetaminophen-Induced Hepatic Cytotoxicity via Activating JAK2/STAT3 Pathway and Autophagy. Applied Microbiology and Biotechnology, 2018, 102(3): 1443-1453.
2. X Jiang, Y Bao, H Liu, X Kou, Z Zhang, F Sun, Z Qian, Z Lin, X Li, X Liu, L Jiang and Y Yang. VPS34 stimulation of p62 phosphorylation for cancer progression. Oncogene, 2017, 36: 6850-6862
3. Xinhui Kou, Yonghua Yang, Xiaoxiao Jiang, Huijuan Liu, Fanghui Sun, Xuan Wang, Longkai Liu, Hongrui Liu, Zhaohu Lin, Lan Jiang. Vorinostat and Simvastatin have synergistic effects on triple-negative breast cancer cells via abrogating Rab7 prenylation. European Journal of Pharmacology. 2017, 813:161-171
4. Yang Shen, Linyi Meng, Huajun Sun, Yizhun Zhu, Hongrui Liu*. Cochinchina Momordica Seed Suppresses Proliferation and Metastasis in Human Lung Cancer Cells by Regulating Multiple Molecular Targets. The American Journal of Chinese Medicine, 2015, 43(1): 149-166
5. Hui Xie, Di Jin, Yun Kang, Xueru Shi, Hongrui Liu, Haixing Shen, Jian Chen, Macheng Yan, Juan Liu and ShengLi Pan. The effect of Piper laetispicum extract (EAEP) during chronic unpredictable mild stress based on interrelationship of inflammatory cytokines, apoptosis cytokines and neurotrophin in the hippocampus. BMC Complementary and Alternative Medicine, 2015,15:240-250
6. Huajun Sun, Linyi Meng, Yang Shen, Yizhun Zhu, Hongrui Liu*. S-benzyl-cysteine-mediated Cell Cycle Arrest and Apoptosis Involving Activation of Mitochondrial-dependent Caspase Cascade through the p53 Pathway in Human Gastric Cancer SGC-7901 Cells. Asian Pac J Cancer Prev, 2013,14(11), 6379-6384
7. Cheng Xie, Jun Chang, Xiaodong Hao, Jianming Yu, Hongrui Liu*, Xun Sun*. Mitochondrial-targeted prodrug cancer therapy using a rhodamine B labeled fluorinated docetaxel. Eur J Pharm Biopharm. European Journal of Pharmaceutics and Biopharmaceutics.2013, (85): 541-549
8. Chen Zhang#, Hongrui Liu#, Qing Yang, Jun Chang*, Xun Sun*. Synthesis and Cytotoxic Evaluation of Novel Platinum (II) Complexes with C2-Asymmetric and C2-Symmetric Chiral Vicinal Diamines. Chinese Journal of Chemistry. 2013, (31): 154-158
9. Qi Wang#, Hongrui Liu#, Tingting liu, Shizhen Shu, He Jiang, Shidan Cheng, Yaozong Yuan, Weiguo Yang, and Lifu Wang*. BRCA2 Dysfunction Promotes Malignant Transformation of Pancreatic Intraepithelial Neoplasia. Anti-Cancer Agents in Medicinal Chemistry. 2013, (13): 261-269
Patents
1. Liu Hongrui, Yu Yunqiu, Meng Linyi. Application of bioactive extracts from Trionyx sinensis in the preparation of anti-respiratory tumor drugs. Patent Number ZL 2011 1 0442495.X
2. Yu Yunqiu, Liu Hongrui, Lin Zhiyan. A kind of extract of soft-shelled turtle and its extraction method and use. Patent Number ZL 2011 1 0442493.0
3. Chen Ying, Xia Peng, Liu Hongrui, Li Guoxiong. 7-oxygen, sulfur or nitrogen impurities substituted for coumarin and its derivatives and uses. Patent number ZL 201210165359.5
4. Zhu Yizhun, Huang Chengrong, Kan Juntao, Liu Hongrui. A solid dispersion of propyl-cysteine and its preparation method and application. Patent number ZL2013 1 0107350.3
